Health technology assessments published by HAS in September 2022

12

Oct 2022

In September 2022, the French National Authority for Health (HAS) published four new opinions, which were based on health technology assessment reports. They are related to neuromodulation and cardiovascular areas. The main goal of these HTA was to support decision-making for the creation of new procedure codes in the Common Classification of Medical Procedures (CCAM) and to update the indications for implantable cardiac defibrillators with endocavitary lead(s) in the Intra-DRG list.

The French National Authority for Health (HAS) published three favorable opinions for the registration of three procedures related to the use of the INSPIRE IV device, upper airway stimulation system, in the CCAM Nomenclature  (sufficient actual benefit and level IV of clinical added value) based on the CNEDiMTS assessment “INSPIRE IV Upper Airway Stimulation System” of March 29, 2022:

  • Favorable opinion for the procedure of implantation of INSPIRE IV device with the registration of the act “Implantation of a hypoglossal nerve stimulation system” in the CCAM Classification;
  • Favorable opinion for the procedure of replacement of INSPIRE IV device with the registration of the act “Replacement of a hypoglossal nerve stimulation system (pulse generator or electrodes)” in the CCAM Classification;
  • Favorable opinion for the procedure of removal of INSPIRE IV device with the registration of the act “Removal of a hypoglossal nerve stimulation system (pulse generator or electrodes)” in the CCAM Classification.

The following indications for the use of INSPIRE IV device, upper airway stimulation system, were set out in the CNEDIMTS note: Treatment of moderate to severe obstructive sleep apnea-hypopnea syndrome (OSAHS) (15 ≤ apnea-hypopnea index (AHI) ≤ 50) in patients with a body mass index (BMI) of less than 32 kg/m² and treatment failure (non-responders or non-compliant) by continuous positive airway pressure (CPAP) and by mandibular advancement orthosis (MAO) in the indications defined by the List of Reimbursable Products and Services (LPPR).

Regarding the cardiovascular devices, single, double, and triple chamber implantable automatic cardiac defibrillators with endocavitary lead(s) are currently registered under the generic description on the list of health products so-called Intra-DRG (Intra-GHS) List.

The HAS opinion was based on the health technology assessment report “Reassessment of implantable cardiac defibrillators with endocavitary lead(s)”– the aim was to update the previous report of 2015, specifically, the indications for single, double, and triple chamber ICDs with regard to the recommendations for good practice, the minimum technical specifications of these devices, and their methods of prescription and use. The National Commission for the Evaluation of Medical Devices and Health Technologies (CNEDiMTS) recommended renewing the conditions for the inclusion of conventional implantable cardiac defibrillators with endocavitary probes (single, double, and triple chamber) on the Intra-DRG list in the form of generic descriptions in accordance with the proposed nomenclature.

See the details in French here (INSPIRE IV device) and here (implantable cardiac defibrillators)

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). First EU issues of both newsletters are available for download free-of-charge.

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).

The latest related news

24

Mar 2023

On March 2, 2023, the decision of the National Union of Health Insurance Funds relating to the update of the CCAM Nomenclature of procedure codes was published in the Official Journal of the French Republic. Changes include registration of new procedure codes, modification and removal of some existing codes. Newly introduced codes concern cardiovascular procedures, interventional radiology, orthopedics, peripheral vascular procedures, and others.

Read more

23

Mar 2023

In February 2023, the Scottish Health Technology Group, SHTG, released three MedTech-related assessments: selective internal radiation therapies (SIRT) for treating primary hepatocellular carcinoma, Feeling Good app, store-and-forward teledermatology for triage of primary care referrals.

Read more

21

Mar 2023

On March 8, 2023, the Ministry of Health and Prevention published an Order in the Official Journal of the French Republic on the coverage of the INTERVAPOR system for lung volume reduction under Forfait innovation program.

Read more

16

Mar 2023

In January-February 2023, Health Technology Wales published sixteen Medtech-related Topic Exploration Reports (TER), including stereotactic radiosurgery, percutaneous implantation of pulmonary artery pressure sensors, ambulatory patch ECG devices, and others; however, Health Technology Wales will not proceed with full appraisals on these topics. No Guidance was released for Medtech in January-February 2023.

Read more

15

Mar 2023

In March 2023, a new ‘AI and Digital Regulations Service’ for developers and adopters of artificial intelligence (AI) and digital technologies was launched in England. Four organizations provide this multi-agency advisory service: NICE, Care Quality Commission, Medicines and Healthcare products Regulatory Agency, and Health Research Authority. The website is currently in public beta and focused on information for developers.

Read more